The DayOne Accelerator Program for Healthtech Startups is now accepting applications for its three-month hybrid program based in Basel, Switzerland, according to a recent announcement. The program targets early-stage healthtech and techbio ventures developing solutions to support pharmaceutical research and development. The application period is open until the deadline of May 31, 2026.
This initiative provides a structured, equity-free, and fee-free opportunity for emerging companies in the life sciences sector. For startups operating at the pre-seed to Series A stage, the program offers access to potential non-dilutive funding and support without requiring them to give up ownership. The immediate consequence is that eligible global startups can now apply for a spot in the cohort, which includes financial support for travel and the possibility of follow-on funding after completion.
What We Know So Far
- The DayOne Accelerator is inviting applications from healthtech and techbio startups with a focus on supporting pharmaceutical R&D, according to a report from www2.fundsforngos.org.
- The program is structured as a three-month hybrid accelerator based in Basel, Switzerland, and is offered on an equity-free and fee-free basis, the announcement states.
- Eligibility is open to global startups from pre-seed to Series A funding stages, provided they have raised less than USD 10 million in total dilutive funding.
- Selected ventures may receive up to CHF 1,000 in travel support for an initial bootcamp and could be eligible for up to CHF 50,000 in post-program non-dilutive funding.
- The final deadline for all applications to the DayOne Accelerator program is May 31, 2026.
What is the DayOne Accelerator Program?
The DayOne Accelerator Program is a specialized initiative designed to support emerging companies in the health technology and technology-biology sectors. According to its public call for applications, the program’s primary focus is on startups that are creating innovative solutions to advance and support pharmaceutical research and development (R&D). This specific focus suggests an interest in technologies that can streamline drug discovery, improve clinical trial processes, or enhance data analysis within the pharmaceutical industry.
The program is structured as a three-month hybrid accelerator. This model typically combines remote participation with required in-person sessions, offering flexibility for globally-distributed teams. The in-person components are based in Basel, Switzerland, a city known for its concentration of pharmaceutical and life sciences companies. The program’s structure aims to provide a concentrated period of development and mentorship for the selected startups over its three-month duration.
A key feature highlighted in the announcement is that the accelerator is both equity-free and fee-free. This model is distinct from many traditional accelerator programs that require startups to exchange a percentage of their company’s equity for participation and funding. By being equity-free, the DayOne Accelerator allows founders to retain full ownership of their companies. The fee-free aspect removes a potential financial barrier to entry, making the program accessible to early-stage ventures that may have limited operational capital.
Funding and Support for Healthtech Startups
The DayOne Accelerator Program outlines two main financial components to support participating startups, according to the program details. The first is direct financial assistance for travel. Selected ventures may receive up to CHF 1,000 to help cover the costs associated with attending the initial in-person bootcamp in Basel. This support is intended to reduce the logistical and financial burden on international teams or founders with limited resources, ensuring they can participate in the critical kickoff phase of the program.
The second, and more substantial, financial opportunity is the potential for post-accelerator funding. The announcement states that ventures may be eligible for up to CHF 50,000 in non-dilutive funding after completing the program. Non-dilutive funding is a form of capital that does not require the startup to give up equity or ownership. This type of financing, often provided through grants or forgivable loans, is highly sought after by early-stage companies as it allows them to secure capital for growth without diluting the ownership stakes of the founders and initial investors.
DayOne Accelerator Program: Eligibility and Application Process
The DayOne Accelerator Program has established eligibility criteria targeting early-stage companies. According to the announcement, the program is open to startups globally, with no geographical restrictions. Companies must be from pre-seed to Series A stage, a range that covers ventures from the earliest stages of ideation and product development up to those with market traction seeking to scale.
A key financial constraint for applicants is a requirement to have raised less than USD 10 million in dilutive funding. This cap specifically ensures the program remains focused on ventures still in their nascent stages, which have not yet secured substantial institutional investment. The application process is currently open, requiring interested startups to submit all materials by the final deadline of May 31, 2026. Details regarding the selection timeline or the program cohort's scheduled start date have not yet been provided.
